- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01153555
Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy (FIRST)
Fractional Flow Reserve and Intravascular Ultrasound RelationShip STudy: The FIRST Study
Study Overview
Status
Conditions
Detailed Description
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Washingtoon Hospital Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Sign written informed consent to participate in the study.
- Clinical indication for coronary angiography for stable or unstable angina
Specific Angiographic Inclusion Criteria:
- Patients required to have an intermediate coronary lesion (stenosis 40-80% by visual estimate) in one or more native, major epicardial coronary artery with reference diameter ≥2.5mm (visual estimate)
- The vessel(s) with the intermediate lesion must have no flow limiting lesions and must be available for imaging and must be considered safe for imaging evaluation.
Exclusion Criteria:
- Patient has had a documented acute ST-segment elevation myocardial infarction within the past 24 hours
- Decompensated heart failure or hypotension requiring intubation, inotropes, intravenous diuretics or intraaortic balloon counterpulsation.
- Renal dysfunction (creatinine clearance < 60 mL/min/1.73m2)
- Pregnancy or breast-feeding
- Standard contra-indications to MRI for implanted ferro-magnetic devices - i.e.: pacemakers, defibrillator (AICD), and aneurysm clips
- Body weight > 400lbs
- Left ventricular hypertrophy >1.5cm by by echocardiogram
- History of bronchospasm or asthma
- ECG evidence of conduction defect, including 2nd or 3rd degree AVB
- Patient has a known hypersensitivity, allergy or contraindication to gadolinium-based contrast agents.
- Prior participation in this study or patient is currently enrolled in another investigational use device or drug study that has not reached its primary endpoint. If the patient is enrolled in another study that is not investigational, required visits for that trial must not interfere with the conduct of this trial.
Angiographic Exclusion Criteria:
- Unprotected left main lesion location.
- Ostial lesion
- Angiographic evidence of severe calcification or marked tortuosity of the target vessel that would preclude safe imaging
- Lesion is located within or distal to an arterial or saphenous vein graft.
- Angiographic presence of thrombus in the lesion or vessel studied.
- Lesion in a vessel with <2.5 mm reference diameter or with more than one lesion in the vessel
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
|---|
|
Intermediate coronary lesions
Diagnostic device: FFR Diagnostic device: IVUS RF At participating centers, FFR and IVUS are standard of care diagnostic procedures for patients with intermediate (40-80% angiographic stenosis by visual estimate). Both modalities were used regularly for such patients whether or not they are participants in this clinical study. In FIRST, the decision to perform percutaneous coronary intervention (PCI) was left to the discretion of the investigator, and was not dictated by the clinical protocol. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between (Minimum Luminal Area) MLA and FFR
Time Frame: Day of Procedure
|
The correlation between MLA and FFR; and the threshold value for MLA corresponding to an FFR < 0.8.
|
Day of Procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Correlation between FFR and IVUS and VH parameters
Time Frame: Day of Procedure
|
Correlation between FFR and various IVUS measurements (MLA,area stenosis, lesion length, plaque burden) and VH parameters (plaque type and presence of a TCFA)
|
Day of Procedure
|
|
Association of FFR and Cut-off of MLA
Time Frame: Day of Procedure
|
Assess the association between FFR <0.75 and 0.8 and determined cut-off of MLA with presence of a Thin Cap Fibro-Atheroma(TCFA) and/or plaque burden ≥70%
|
Day of Procedure
|
|
Identify risk score model
Time Frame: 1 year
|
To identify a risk score model taking into account IVUS measurements (MLA, plaque burden, area stenosis, lesion length) and VH parameters (plaque type and presence of TCFA) associated with FFR < 0.8
|
1 year
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Ron Waksman, MD, Medstar Health Research Institute
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- FIRST
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.